Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS.

Cancer medicine·2025
Same author

Magnetic Resonance Imaging as a Tool for Monitoring Intratibial Growth of Experimental Prostate Cancer Metastases in Mice.

Methods and protocols·2023
Same author

Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).

Acta oncologica (Stockholm, Sweden)·2023
Same author

Osteoclasts directly influence castration-resistant prostate cancer cells.

Clinical & experimental metastasis·2022
Same author

Androgens, aging, and prostate health.

Reviews in endocrine & metabolic disorders·2022
Same author

Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.

The Journal of urology·2022

Related Experiment Video

Updated: Jul 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate cancer.

Jan-Erik Damber1, Gunnar Aus

  • 1Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Lancet (London, England)
|May 20, 2008
PubMed
Summary
This summary is machine-generated.

Prostate cancer is a common diagnosis, but increased screening means many low-risk cases are found. Most diagnosed prostate cancers do not become life-threatening, indicating overdiagnosis is a concern.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Related Experiment Videos

Last Updated: Jul 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Area of Science:

  • Oncology
  • Urology
  • Public Health

Background:

  • Prostate cancer is the second most diagnosed cancer and third leading cause of cancer death in men globally.
  • A positive family history is a significant risk factor, alongside age and ethnicity.
  • Current treatments like androgen deprivation are effective short-term but often lead to incurable relapse.

Purpose of the Study:

  • To analyze trends in prostate cancer incidence and mortality.
  • To evaluate the impact of screening and diagnostic advancements.
  • To assess the progression rate of low-risk prostate cancers.

Main Methods:

  • Review of epidemiological data on prostate cancer incidence and mortality.
  • Analysis of factors influencing diagnosis, including PSA screening and biopsy techniques.
  • Evaluation of treatment outcomes and relapse rates in advanced prostate cancer.

Main Results:

  • Prostate cancer incidence has risen significantly due to screening and improved diagnostics.
  • Mortality trends are less clear, with some countries showing stable or decreased rates.
  • A small proportion of diagnosed low-risk prostate cancers progress to life-threatening stages.

Conclusions:

  • The disparity between rising incidence and stable/decreasing mortality suggests overdiagnosis of low-risk prostate cancer.
  • Screening and diagnostic improvements have increased detection but not necessarily improved survival outcomes proportionally.
  • Further research is needed to differentiate indolent from aggressive prostate cancers to optimize treatment strategies.